Mediar Therapeutics

US-based clinical-stage biotech Mediar Therapeutics, Inc. has announced a global license agreement with Eli Lilly and Company (NYSE: LLY) to advance its investigational drug MTX-463 into a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). This strategic partnership aims to further develop and potentially bring to…